Core Insights - Lucid Group's stock has declined over 60% since the beginning of the year, significantly underperforming compared to the S&P 500, which has risen approximately 13% during the same period [1] - Despite the bullish long-term outlook for electric vehicles (EVs), maintaining a position in Lucid may not be sensible due to the presence of competitors with clearer paths to profitability [2] Company Performance - Lucid's stock price has seen a dramatic decline, losing over 98% of its value since its peak of $580.50 per share five years ago when it was a SPAC [3][4] - For the quarter ending September 30, 2025, Lucid reported revenue of $336.6 million, a year-over-year increase of more than 68%, but operating cash burn rose to $756.6 million, up 63.5% from the previous year [5] - The company has been relying on dilutive equity sales and convertible bonds, primarily to its majority shareholder, Saudi Arabia's Public Investment Fund (PIF), which has contributed to long-term stock price erosion [6][8] Market Context - Recent changes in U.S. Federal EV policy have caused domestic sales to stall, yet long-term forecasts indicate that EVs will capture a larger share of the vehicle market [9] - Globally, EV sales have increased by 21% this year, indicating a positive trend in the overall market despite challenges faced by individual companies like Lucid [9]

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly making false and misleading statements regarding its business operations and prospects during the class period from June 6, 2024, to November 10, 2025 [1][2]. Summary by Sections Allegations Against Defendants - The complaint claims that Bitdeer misrepresented its SEAL04 chip design progress, leading to production delays [2] - Bitdeer adopted a "dual-track approach" to create two independent designs to compensate for lost progress, while still assuring the public that production timelines were on track [2] - As a result, the statements made by the defendants regarding the company's business and operations were materially false and misleading [2] Lead Plaintiff Process - Investors in Bitdeer can seek to be appointed as lead plaintiff by February 2, 2026, or choose to remain absent from the class [3] - The lead plaintiff will represent all class members and select counsel to direct the litigation [3] - Participation as a lead plaintiff does not affect the ability to share in any recovery [3] About Kessler Topaz Meltzer & Check, LLP - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection [4] - The firm has a strong track record in securities litigation and has received numerous accolades for its work [4] - KTMC operates globally with offices in Pennsylvania and California [4]

Core Viewpoint - Applied Digital (NASDAQ: APLD) shares experienced a significant increase of 16.5% on Friday, following a notable decline of 17.5% just two days earlier [1] Company Summary - The stock price recovery indicates a volatile trading environment for Applied Digital, highlighting investor reactions to recent market movements [1]

If we took a single 10-week strand of pricing data from Oracle (ORCL), the return during this period won’t tell us much about the performance probability of the other weeks. However, if we took hundreds of rolling 10-week sequences of ORCL stock and arranged them in a distribution, the most frequent, consistent performances would lead to bulges in probability mass. These bulges represent risk geometry, which allows us to make smarter decisions.Instead, we need to think in terms of probabilistic mass and ris ...

Core Insights - The article compares two mining ETFs: Global X - Silver Miners ETF (SIL) and VanEck Gold Miners ETF (GDX), highlighting their differences in expense ratios, portfolio breadth, and risk profiles for investors seeking precious metals exposure [2][8]. Expense Ratios and Performance - GDX has a lower expense ratio of 0.51% compared to SIL's 0.65%, making it more cost-effective for investors [3] - Both ETFs have shown a 1-year return of 151% as of December 16, 2025, indicating strong performance in the precious metals sector [3] - GDX offers a lower dividend yield of 0.5% versus SIL's 1.08%, which may attract income-focused investors [3] Portfolio Composition - GDX provides exposure to 56 gold mining companies, primarily large-cap, with significant holdings in Agnico Eagle Mines Ltd, Newmont Corp, and Barrick Mining Corp, reflecting a diversified approach [5] - SIL focuses exclusively on silver miners, holding 39 stocks, with top positions in Wheaton Precious, Pan American Silver Corp, and Coeur Mining Inc, appealing to those seeking direct silver exposure [6] Market Context - Precious metals investing is seen as a hedge against inflation and a means of portfolio diversification, with silver prices recently reaching an all-time high and gold steadily rising [9] - Silver is noted for its higher volatility compared to gold due to its dual role as an industrial metal and a store of value, while gold is primarily viewed as a safe haven during economic or political instability [10] Risk Considerations - Both ETFs are focused on mining companies, which carry specific operational risks that can affect stock performance independently of the precious metals they mine [11]

Core Insights - Bitcoin demand has weakened recently, with ETF holdings declining and large investors accumulating more slowly, indicating a potential bear market [1][2][4] - The report suggests that most of the demand growth cycle for Bitcoin has passed, leading to bearish price effects [2][4] - Bitcoin's price has dropped 30% from its all-time high of over $126,000, currently trading just above $88,000 [2][5] ETF Holdings and Investor Behavior - U.S.-based spot Bitcoin ETFs became net sellers in Q4 2025, with holdings decreasing by approximately 24,000 BTC, equivalent to around $2.12 billion [3] - There has been weaker growth among addresses holding between 100 and 1,000 BTC, which includes ETFs and corporate treasury accounts [3][4] Price Trends and Market Indicators - Bitcoin has crossed below its 365-day moving average, a significant technical threshold that historically indicates a transition from bull to bear markets [4] - Historical patterns suggest that downturns typically follow periods of peak demand growth, with a potential cycle low projected at $56,000, representing a 55% drop from the all-time high [5][6] - Intermediate price support is identified around the $70,000 level [5] Market Context and Future Outlook - The report highlights a record $19 billion liquidation event in October, contributing to the recent declines in Bitcoin and other top assets [6] - Despite the bearish outlook, some analysts maintain bullish perspectives for Bitcoin into 2026, suggesting that traditional price cycles may no longer apply [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026, for a class action lawsuit related to alleged misrepresentations about the company's sleep apnea device, Inspire V [1][5]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit a form online or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by January 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [4]. Group 3: Allegations Against Inspire Medical - The lawsuit claims that Inspire Medical misrepresented key facts about the market demand for its Inspire V device and failed to disclose whether necessary steps for its launch were taken, leading to misleading statements that inflated investor confidence [5]. - When the true details about the product and its market performance became known, investors allegedly suffered damages [5].

Core Viewpoint - Medicus Pharma has completed patient enrollment in its SkinJect clinical trial, marking a significant milestone in the development of a noninvasive treatment for basal cell carcinoma, the most common skin cancer [1][4]. Company Overview - Medicus Pharma is advancing its clinical development program for SkinJect, a novel treatment targeting non-melanoma skin diseases, particularly basal cell carcinoma [3][4]. - The company has been working on this project since the fall of 2023, with patient recruitment starting in August 2024 [4]. Clinical Trial Details - The clinical trial has enrolled 90 patients across nine sites in the United States [1][4]. - The company aims to present topline data in Q1 2026 and plans to sync with the FDA for an end-of-phase-two meeting in the first half of next year [4][8]. Treatment Methodology - SkinJect utilizes uniquely designed microneedle arrays developed from Carnegie Mellon and the University of Pittsburgh, allowing for direct application of a chemotherapeutic agent, doxorubicin, to the cancer site [6]. - This method is intended to trigger an immunogenic response and effectively kill cancer cells [6]. Market Context - Non-melanoma skin diseases, especially basal cell carcinoma, account for 5 million new cases annually in the United States and over 30 million globally [5]. - Traditional treatments like Mohs surgery are expensive and painful, highlighting the need for a more cost-effective and aesthetically pleasing alternative [5][7]. Future Outlook - The company is optimistic about the upcoming topline data and the potential for a Priority Review Voucher from the FDA, which could expedite the new drug application timeline by 10-12 months [8][9]. - The NDA is expected to be filed in late 2027 or early 2028, aligning with the company's positive momentum [8][9].

Core Insights - Nebius Group (NASDAQ: NBIS) experienced significant stock volatility, with shares dropping nearly 15% before recovering to close the week 2% higher than the previous Friday's close, as investors assessed the potential revenue realization from its contract backlog [1][6] Financial Position - Nebius is in a relatively strong financial position compared to its peer, CoreWeave, despite taking on debt to expand its capacity. Nebius currently has negative net debt, indicating it has more cash than debt [3][4] - The company's stock is priced based on expectations of achieving an annual revenue run rate between $7 billion and $9 billion by the end of 2026, a significant increase from an anticipated $1 billion run rate at the end of the current quarter [6][8] Market Sentiment - Concerns over rising debt levels in the AI infrastructure sector have led to investor anxiety, particularly highlighted by CoreWeave's high debt position. This has contributed to the selling pressure on Nebius shares earlier in the week [3][4] - The recovery in Nebius's stock price was partly influenced by Citigroup's "buy" rating for CoreWeave, suggesting a potential 100% upside for that stock, which positively affected sentiment across the sector [4][5] Revenue Risks - There is a risk that if customers reduce their spending on long-term agreements worth billions with Nebius, the anticipated revenue growth may not materialize, leading to further stock price volatility [5][6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, about the January 9, 2026, deadline to become a lead plaintiff in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by January 9, 2026, to serve as lead plaintiff, representing other class members [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Telix's progress with prostate cancer therapeutic candidates and the quality of its supply chain and partners, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].